January 26, 2006
FDA Approves Stomach, Kidney Cancer DrugTopics: Medical Science News
A new drug that combats both a rare stomach cancer and advanced kidney cancer has been approved by the FDA. Sunitinib, which will be marketed by Pfizer Inc. as Sutent, is the first cancer drug to simultaneously win Food and Drug Administration approval for two conditions. The FDA granted the medication priority review as a kidney cancer drug and approved it just six months later because its usefulness in treating the serious and life-threatening diseases. A trial of Sutent as a stomach cancer treatment was cut short after the drug's ability to delay tumor growth prompted researchers to give the Pfizer drug to patients who had been taking placebos.
SUTENT is a highly selective, multi-targeted tyrosine kinase inhibitor that starves tumors of blood and nutrients needed for growth and simultaneously kills cancer cells that make up tumors.
Companion post at Hyscience
Image Source - GSI
Posted by Richard at January 26, 2006 10:48 PM
Articles Related to Medical Science News: